Long Chau expands into medical testing, free home sampling within 10 km
This Aveluro analysis covers FRT on HOSE in the Retail sector. The classified event type is strategic partnership, with positive sentiment and a deterministic market-impact score of 5.0/10. Aveluro classifies this story as a positive catalyst in the stock's news coverage. Source coverage came from CafeF - Thị trường chứng khoán, classified as a primary/top-tier source.
Key Facts
Caveat: Not investment advice. · How Aveluro computed this: Aveluro combines extracted event facts, source credibility, ticker context, and market data. Scores are deterministic research signals, not recommendations.
Overview
FPT Retail (FRT) has announced that its Long Chau pharmacy chain is expanding into medical testing services, partnering with Gene Solutions and LabHouse. The new service, branded as Xét nghiệm Long Châu, offers a range of tests from routine blood work to cancer screening, with free home sample collection within 10 km. This strategic move positions Long Chau as a more comprehensive healthcare provider, building on its existing pharmacy and vaccination networks.
Key Facts
- Long Chau has launched a medical testing system, Xét nghiệm Long Châu, offering services such as blood tests, blood sugar, lipid panels, liver and kidney function, and cancer screening.
- The service is delivered through a four-step process: free doctor consultation, scheduling, sample collection (at center or home), and online results via SMS or email.
- Long Chau has partnered with Gene Solutions and LabHouse, whose labs meet ISO 15189:2022 standards.
- Currently, there are 5 sample collection points in Hồ Chí Minh City, Bình Dương, and Đồng Nai, with plans to expand nationwide.
- Home sample collection is free within a 10 km radius; for 10-15 km, orders above 500,000 VND are free, while orders below that incur a 50,000 VND fee.
- As of end-June 2026, Long Chau operates 2,639 pharmacies and 236 vaccination centers.
- FRT shares closed at 124,400 VND on August 2, 2026, on HOSE.
What Happened
Long Chau, the pharmacy chain under FPT Retail, has officially introduced its medical testing service, according to an announcement on its website. The service aims to provide technology-enabled medical testing following international standards. Customers can choose from a variety of tests, including routine health checks and cancer screening packages tailored to age and needs.
The process involves a free consultation with a doctor, then scheduling a sample collection either at a Long Chau testing point or at home. Results are delivered online via SMS or email. To ensure quality, Long Chau has formed strategic partnerships with Gene Solutions and LabHouse, which operate laboratories certified to ISO 15189:2022.
Currently, five sample collection points are operational in Hồ Chí Minh City, Bình Dương, and Đồng Nai, with further expansion planned. The home sampling service covers up to 15 km, with free collection within 10 km and conditional free collection for longer distances.
Market Context
FRT, listed on HOSE, has seen its share price close at 124,400 VND on August 2, 2026. The company has been diversifying its healthcare offerings beyond traditional pharmacy retail, having already built a large network of vaccination centers. This move into diagnostics aligns with the broader trend of retail pharmacies expanding into higher-margin services. In the Vietnamese market, healthcare spending is rising, and players like Long Chau are positioning to capture more of the value chain.
Strategic Significance
For long-term investors, this expansion represents a logical extension of FRT’s healthcare ecosystem. By adding diagnostic services, Long Chau can cross-sell to its existing customer base, increase foot traffic, and enhance patient loyalty. The partnership with established lab providers mitigates the need for heavy capital investment in laboratory infrastructure. This move could also differentiate Long Chau from competitors and potentially improve margins over time, as services typically carry higher margins than product sales. However, execution risks remain, including regulatory compliance and scaling the service network efficiently.
What to Watch
- Expansion of sample collection points to additional provinces and cities.
- Customer adoption rates and revenue contribution from testing services in upcoming quarterly reports.
- Any regulatory changes affecting home-based medical testing services.
- Competitive responses from other pharmacy chains or diagnostic centers.
- Updates on partnership terms with Gene Solutions and LabHouse, including any exclusivity clauses.